Alibaba Health (0241) Stock Price, Fundamentals & Analysis

What 0241 does

Alibaba Health (0241) is a stock listed on the Hong Kong Stock Exchange in the Healthcare sector, specifically within the Pharmaceutical Retailers industry. The company, headquartered in Causeway Bay, Hong Kong, operates as an investment holding company focused on pharmaceutical direct sales, pharmaceutical e-commerce, and digital healthcare services across China. Its flagship platform, Alibaba Health, integrates online and offline medical resources to provide one-stop healthcare solutions. The business covers a wide range of products, including prescription and over-the-counter drugs, nutritional supplements, medical devices, contact lenses, and healthcare food, as well as services such as medical checkups, testing, consultation, vaccination, dentistry, psychology, optometry, and traditional Chinese medicines. It also engages in digital tracking, asset management, and the operation of internet hospitals. Within the broader Hong Kong healthcare landscape, peers include WuXi Biologics (2269), CSPC Pharmaceutical Group (1093), Hansoh Pharmaceutical Group (3692), WuXi AppTec (2359), Sino Biopharm (1177), and Sinopharm Group (1099).

Key numbers explained

• 2.83 HKD is the current price per share, representing the cost to buy one unit of the company on the market today.
• 0% price change today indicates the stock has not moved from its previous close during the current trading session.
• 45.7 mld. HKD market capitalization is the total value of all outstanding shares, calculated by multiplying the share price by the number of shares.
• 20.2 trailing P/E ratio shows how much investors pay per unit of earnings the company has already earned over the last 12 months; a higher number can suggest higher expectations for future growth.
• 15 forward P/E ratio is based on expected future earnings and is often used to gauge whether a stock might be expensive or cheap relative to what analysts anticipate.
• 0.14 CNY earnings per share (trailing 12 months) is the portion of the company's profit allocated to each outstanding share.
• 2.43% dividend yield represents the annual dividend payment as a percentage of the current share price, indicating the cash return shareholders receive relative to the stock's price.
• 1.59 beta measures the stock's volatility compared to the overall market; a beta above 1 means it tends to move more than the market.
• -56.8% price change over the last 52 weeks shows the stock has declined significantly from its level one year ago.
• 34.26 mld. CNY revenue (trailing 12 months) is the total value of goods and services sold during the period.
• 5.7% profit margin indicates that for every unit of revenue, the company retains 5.7% as profit after all expenses.
• 0.3 debt-to-equity ratio expresses the company's financial leverage, showing that debt is 30% of shareholders' equity.

What to watch

Investors tracking Alibaba Health (0241) typically monitor factors common to healthcare and pharmaceutical retail stocks. Regulatory changes in China's healthcare and e-commerce sectors can materially affect the company's operations and pricing. The company's ability to grow revenue, which grew 7.6% year over year to 34.26 mld. CNY, depends on consumer demand, competition from peers such as WuXi Biologics (2269) and CSPC Pharmaceutical Group (1093), and the success of its digital healthcare initiatives. The wide 52-week price range of 2.75 – 7.91 HKD reflects significant volatility, which is partly captured by the 1.59 beta. The 0% share of earnings paid out as dividends means the current dividend yield of 2.43% is not funded by the company's own earnings, a detail worth understanding for income-focused investors. The ex-dividend date of 12 aug. 2026 is the key calendar event for anyone interested in receiving the next dividend payment.